DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

Information source: University Hospital Freiburg
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Depression

Intervention: CBASP psychotherapy (Other); Escitalopram (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University Hospital Freiburg

Official(s) and/or principal investigator(s):
Claus Normann, MD, Principal Investigator, Affiliation: University of Freiburg, Dep. of Psychiatry
Dieter Schoepf, MD, Principal Investigator, Affiliation: University of Bonn, Clinic for Psychiatry and Psychotherapy


60 patients with chronic major depressive disorder according to DSM-IV will be included into the study. Patients will be randomized to receive an open treatment either with CBASP, a psychotherapy for chronic depression, or pharmacological treatment with Escitalopram for 28 weeks.

Clinical Details

Official title: Differential Responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)Versus Escitalopram in Chronic Major Depression With and Without Early Trauma

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Depressive symptomatology after 8 weeks after randomization as measured by the MADRS

Secondary outcome: Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization

Detailed description: The psychotherapeutic treatment with CBASP will be conducted in 2 weekly sessions for the first 4 weeks, one per week thereafter until week 9, followed by one session every 2 weeks for 20 more weeks. The starting dose for Escitalopram will be 10 mg/d for one week and will be increased to 20 mg/d after one week. The dosage can be reduced to 10 mg/d after day 7 to improve tolerance. Th MADRS-scale is the primary outcome measure; ratings will be performed by a blinded rater. If there is no improvement (reduction of less than 20% of the MADRS), patients will be crossed over in terms of adding the other treatment at week 8. Study patients will be asked to participate in fMRI, genetic and pharmacological substudies.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least

one year), or recurrent MDE (third or greater episode with the immediately preceding episode being no more than 2. 5 years before the onset of the present episode)

- Age 18-65

- Score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)

Exclusion Criteria:

- Acute risk for suicide

- History of psychotic symptoms, bipolar disorder or dementia

- Severe substance-related abuse or dependence disorder

- Schizotypal, antisocial or borderline personality disorder

- Serious medical condition

- Severe cognitive impairment

- Absence of a response to previous adequate trial of the study medication/CBASP

- Hypersensitivity to Escitalopram

- Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment

Locations and Contacts

University of Bonn, Dept. of Psychiatry, Bonn D-53105, Germany; Recruiting
Dieter Schoepf, MD, Email: dieter.schoepf@ukb.uni-bonn.de
Dieter Schoepf, MD, Principal Investigator
Henrik Walter, MD, PhD, Sub-Investigator

University of Freiburg, Dept. of Psychiatry and Psychotherapy, Freiburg D-79104, Germany; Recruiting
Claus Normann, MD, Phone: +49-761-2706501, Email: claus.normann@uniklinik-freiburg.de
Claus Normann, MD, Principal Investigator
Elisabeth Schramm, PhD, Sub-Investigator

Additional Information

Starting date: February 2009
Last updated: June 29, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017